Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14629938 | 0.86 | — | — | |
| SCHEMBL6680792 | 0.80 | GNAI3 (0.37) | KMT2A | |
| SCHEMBL1649799 | 0.79 | SIGMAR1 (0.41) | MEN1KMT2A | |
| SCHEMBL21192380 | 0.79 | SIGMAR1 (0.41) | MEN1KMT2A | |
| SCHEMBL10640772 | 0.79 | SIGMAR1 (0.41) | MEN1KMT2A | |
| SCHEMBL6973232 | 0.77 | MEN1 (0.37) | MEN1KMT2A | |
| SCHEMBL11807764 | 0.77 | ADH1C (0.47) | — | |
| SCHEMBL6567829 | 0.77 | MEN1 (0.35) | MEN1KMT2A | |
| SCHEMBL15556810 | 0.76 | SIGMAR1 (0.43) | MEN1KMT2A | |
| SCHEMBL8736333 | 0.76 | SIGMAR1 (0.43) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | claimed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | claimed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | claimed |
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | disclosed |
| US-7026514-B2 | Compounds used to treat alcoholism | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2006-04-11 | — | — | US | disclosed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | disclosed |
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2004-09-16 | — | — | US | disclosed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | disclosed |
| EP-1403243-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | Garbil Pharma Investigacion Chile Ltda. (CL) | 2004-03-31 | — | — | EP | disclosed |
| WO-2003004453-A1 | COMPOUNDS USED TO TREAT ALCOHOLISM | GARBIL PHARMA INVESTIGACION CHILE LTDA. (CL) | 2003-01-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040180967-A1 | A physiologically-hydrolysable and acceptable amide of the compound of N,N'-bis(3-aminopropylbenzene-1,4-diamine and an acid;advantage being the anti-alcoholism activity lasts for some time after the treatment period, allowing a decrease in the dose, or a total cure; side effect reduction | NAAA, ADH1A, ADH1C | MEN1 2062/4885KMT2A 1124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.